Alnylam Pharmaceuticals (ALNY) Stock Chart & Stock Price History $317.50 -6.63 (-2.05%) Closing price 07/8/2025 04:00 PM EasternExtended Trading$317.33 -0.17 (-0.05%) As of 07/8/2025 06:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Alnylam Pharmaceuticals Stock Price Performance The Alnylam Pharmaceuticals (ALNY) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has increased 24.64%, with a year-to-date return of 34.93%. In the past month, the stock has increased 4.44%, reflecting recent market activity. As of the latest close, Alnylam Pharmaceuticals traded at $317.50 with a market cap of $41.40 billion and volume of 972,968 shares. Five years ago, the stock traded at $159.03, representing a 99.65% increase over that period. At the time, it had a market cap of $18.48 billion and a volume of 413,475 shares. Receive ALNY Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance-4.35%1 Month Performance+4.44%3 Month Performance+30.51%Year-To-Date Performance+34.93%1 Year Performance+24.64%5 Year Performance+99.65% ALNY Stock Chart for Wednesday, July, 9, 2025 ALNY Chart by TradingView Alnylam Pharmaceuticals Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization07/08/2025$324.13$317.50-2.05%$328.99$315.81972,968 shs$41.40 billion07/07/2025$331.94$324.13-2.35%$328.24$314.101.29 million shs$42.26 billion07/04/2025$331.94$331.94$333.70$327.88431,157 shs$43.28 billion07/03/2025$329.77$331.94+0.66%$333.70$327.88431,157 shs$43.28 billion07/02/2025$322.06$329.77+2.39%$330.00$319.40967,737 shs$43.00 billion07/01/2025$326.09$322.06-1.24%$326.64$315.031.24 million shs$41.99 billion06/30/2025$322.83$326.09+1.01%$327.21$320.57943,507 shs$42.52 billion06/27/2025$318.25$322.83+1.44%$323.20$315.142.05 million shs$42.09 billion06/26/2025$321.94$318.25-1.15%$325.00$315.00663,904 shs$41.50 billion06/25/2025$325.00$321.94-0.94%$324.32$320.71632,571 shs$41.98 billion Get the Latest News and Ratings for ALNY and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 06/24/2025$313.13$325.00+3.79%$326.03$309.961.00 million shs$42.38 billion06/23/2025$309.70$313.13+1.11%$314.78$308.46503,129 shs$40.83 billion06/20/2025$312.32$309.70-0.84%$314.50$308.781.34 million shs$40.38 billion06/19/2025$312.32$312.32$317.54$306.70981,185 shs$40.72 billion06/18/2025$308.71$312.32+1.17%$317.54$306.70981,185 shs$40.72 billion06/17/2025$308.78$308.71-0.02%$309.06$303.31570,555 shs$40.25 billion06/16/2025$307.99$308.78+0.26%$309.63$302.32520,199 shs$40.26 billion06/13/2025$304.67$307.99+1.09%$308.02$300.97571,872 shs$40.16 billion06/12/2025$298.58$304.67+2.04%$307.48$295.82874,326 shs$39.73 billion06/11/2025$302.46$298.58-1.28%$303.85$298.25454,983 shs$38.93 billion06/10/2025$304.00$302.46-0.51%$308.89$301.34514,261 shs$39.44 billion06/09/2025$300.83$304.00+1.05%$306.17$297.67609,634 shs$39.64 billion Related Companies Amgen Stock Price Chart Gilead Sciences Stock Price Chart Vertex Pharmaceuticals Stock Price Chart Regeneron Pharmaceuticals Stock Price Chart Biogen Stock Price Chart Incyte Stock Price Chart United Therapeutics Stock Price Chart Neurocrine Biosciences Stock Price Chart Exelixis Stock Price Chart BioMarin Pharmaceutical Stock Price Chart Receive ALNY Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:ALNY) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alnylam Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alnylam Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
